bivatuzumab
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1999 (NCT02204033)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD44 antigenBINDING AGENT
CD44 binding agent
Specific to variant exon 6-containing CD44
- CD44 antigenINHIBITOR
CD44 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108413 ↗
Also known as
- 99mtc-hmab biwa 4
- bivatuzumab
- bivatuzumab
- biwa 4
- biwa 4 (mab)
- hmab biwa 4
- monoclonal antibody biwa 4
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02204046 | Phase 1 | Jan 1, 2000 | Boehringer Ingelheim |
| NCT02204059 | Phase 1 | Dec 1, 1999 | Boehringer Ingelheim |
| NCT02204033 | Phase 1 | Mar 1, 1999 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 3 | 1 | 1999 |
1 organizations
Page 1 / 1